வில்ஹெல்ம்ஸ் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வில்ஹெல்ம்ஸ் பல்கலைக்கழகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வில்ஹெல்ம்ஸ் பல்கலைக்கழகம் Today - Breaking & Trending Today

Bericht der Uni Stuttgart: 100 Hörsäle technisch aufgerüstet

Bericht der Uni Stuttgart: 100 Hörsäle technisch aufgerüstet
stuttgarter-zeitung.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stuttgarter-zeitung.de Daily Mail and Mail on Sunday newspapers.

Baden Wüberg , Transmission Technology , Research Focus Areas , Wilhelms University , Information Technology , University Council , Senate Of University , Lecture Halls , None Cars , Shuttle Buses , Annual Report , Artificial Intelligence , The Summer Semester , Weeks Time , Director Tungsten Ressel , Ghost Town , Tungsten Ressel , Scientist Inside , Charged Of Teaching Mode , Test Results , Previous Year , Female Representation , Academics Inside , Professor Inside , Third Forward , Her Percentage ,

Dr. Kai Pinkernell, M.D. joins Glycostem's leadership team as Chief Medical Officer

Dr. Kai Pinkernell, M.D. joins Glycostem s leadership team as Chief Medical Officer
OSS, Netherlands, April 1, 2021 /PRNewswire/
Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that Dr. Kai Pinkernell, M.D. joins Glycostem as Chief Medical Officer (CMO). With a strong background in pharmaceutical clinical development and medical affairs management, Dr. Kai Pinkernell will lead the next steps in the clinical development strategy of Glycostem s lead product oNKord
(NK) and viveNK
TM (CAR-NK), cell therapies for treatment of hematologic malignancies and solid tumors.
Dr. Pinkernell has more than 20 years of experience in the development of cell and gene therapies and 15 years of senior management experience, including clinical development strategies and their execution at globally operating biotechnology companies. In addition, Dr. Pinker ....

United States , Los Angeles , Kostenloser Wertpapierhandel , Miltenyi Biotec Gmb , Kai Pinkernell , Troels Jordansen , Marshall School Of Business , Wilhelms University Of Muenster , University Of Southern California , Natural Killer , Chief Medical Officer , Chief Development Officer , Global Head , Clinical Business , Miltenyi Biotec , Acute Myeloid , Doctorate Degree , Wilhelms University , Marshall School , Southern California , Orphan Drug Designation , Good Manufacturing Practice , Myeloid Leukemia , Minimal Residual Disease , Medi Cal , ஒன்றுபட்டது மாநிலங்களில் ,